Voya Investment Management LLC increased its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 11.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,454 shares of the biopharmaceutical company’s stock after purchasing an additional 1,933 shares during the quarter. Voya Investment Management LLC owned 0.10% of Akebia Therapeutics worth $265,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its position in Akebia Therapeutics by 1.2% during the first quarter. Goldman Sachs Group Inc. now owns 49,277 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 608 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of Akebia Therapeutics by 144.3% in the second quarter. TIAA CREF Investment Management LLC now owns 252,123 shares of the biopharmaceutical company’s stock worth $3,623,000 after acquiring an additional 148,940 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in shares of Akebia Therapeutics in the second quarter worth about $607,000. FMR LLC lifted its holdings in shares of Akebia Therapeutics by 11.3% in the second quarter. FMR LLC now owns 1,036,955 shares of the biopharmaceutical company’s stock worth $14,901,000 after acquiring an additional 105,100 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Akebia Therapeutics by 165.4% in the second quarter. Renaissance Technologies LLC now owns 1,025,300 shares of the biopharmaceutical company’s stock worth $14,734,000 after acquiring an additional 639,033 shares during the last quarter. 59.27% of the stock is owned by institutional investors and hedge funds.

Akebia Therapeutics, Inc. (AKBA) opened at $15.13 on Friday. Akebia Therapeutics, Inc. has a fifty-two week low of $7.78 and a fifty-two week high of $20.25.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.07. The business had revenue of $41.28 million during the quarter, compared to analyst estimates of $34.00 million. Akebia Therapeutics had a negative net margin of 137.80% and a negative return on equity of 198.85%. sell-side analysts forecast that Akebia Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Akebia Therapeutics, Inc. (AKBA) Position Raised by Voya Investment Management LLC” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/17/akebia-therapeutics-inc-akba-position-raised-by-voya-investment-management-llc.html.

AKBA has been the subject of a number of research reports. Zacks Investment Research raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Akebia Therapeutics in a report on Wednesday, August 9th. BidaskClub raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. ValuEngine raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Royal Bank Of Canada initiated coverage on shares of Akebia Therapeutics in a report on Thursday, September 14th. They issued a “sector perform” rating and a $17.00 target price for the company. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Akebia Therapeutics has an average rating of “Buy” and an average target price of $20.75.

In related news, SVP Michel Dahan sold 1,398 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $19.64, for a total value of $27,456.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders sold 7,586 shares of company stock valued at $147,289. 7.95% of the stock is owned by company insiders.

Akebia Therapeutics Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics, Inc. (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.